Cytotoxicity of phosphoramidate, bis-amidate and cycloSal prodrug metabolites against tumour and normal cells†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-04-18 DOI:10.1039/D4MD00115J
Rebecca E. Farrell, Harrison Steele, Ryan J. Middleton, Danielle Skropeta and Guo-Jun Liu
{"title":"Cytotoxicity of phosphoramidate, bis-amidate and cycloSal prodrug metabolites against tumour and normal cells†","authors":"Rebecca E. Farrell, Harrison Steele, Ryan J. Middleton, Danielle Skropeta and Guo-Jun Liu","doi":"10.1039/D4MD00115J","DOIUrl":null,"url":null,"abstract":"<p >Phosphonate and phosphate prodrugs are integral to enhancing drug permeability, but the potential toxicity of their metabolites requires careful consideration. This study evaluates the impact of widely used phosphoramidate, bis-amidate, and cycloSal phosph(on)ate prodrug metabolites on BxPC3 pancreatic cancer cells, GL261-Luc glioblastoma cells, and primary cultured mouse astrocytes. 1-Naphthol and 2-naphthol demonstrated the greatest toxicity. Notably, 2-naphthol exhibited an ED<small><sub>50</sub></small> of 21 μM on BxPC3 cells, surpassing 1-naphthol with an ED<small><sub>50</sub></small> of 82 μM. Real-time xCELLigence experiments revealed notable activity for both metabolites at a low concentration of 16 μM. On primary cultured mouse astrocyte cells, all prodrugs exhibited reduced viability at 128 to 256 μM after only 4 hours of exposure. A cell-type-dependent sensitivity to phosph(on)ate prodrug metabolites was evident, with normal cells showing greater susceptibility than corresponding tumour cells. The results suggest it is essential to consider the potential cytotoxicity of phosph(on)ate prodrugs in the drug design and evaluation process.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 6","pages":" 1973-1981"},"PeriodicalIF":3.5970,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00115j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Phosphonate and phosphate prodrugs are integral to enhancing drug permeability, but the potential toxicity of their metabolites requires careful consideration. This study evaluates the impact of widely used phosphoramidate, bis-amidate, and cycloSal phosph(on)ate prodrug metabolites on BxPC3 pancreatic cancer cells, GL261-Luc glioblastoma cells, and primary cultured mouse astrocytes. 1-Naphthol and 2-naphthol demonstrated the greatest toxicity. Notably, 2-naphthol exhibited an ED50 of 21 μM on BxPC3 cells, surpassing 1-naphthol with an ED50 of 82 μM. Real-time xCELLigence experiments revealed notable activity for both metabolites at a low concentration of 16 μM. On primary cultured mouse astrocyte cells, all prodrugs exhibited reduced viability at 128 to 256 μM after only 4 hours of exposure. A cell-type-dependent sensitivity to phosph(on)ate prodrug metabolites was evident, with normal cells showing greater susceptibility than corresponding tumour cells. The results suggest it is essential to consider the potential cytotoxicity of phosph(on)ate prodrugs in the drug design and evaluation process.

Abstract Image

Abstract Image

磷酰胺、双酰胺和环萨尔原药代谢物对肿瘤细胞和正常细胞的细胞毒性
膦酸盐和磷酸盐原药是提高药物渗透性不可或缺的药物,但其代谢物的潜在毒性需要仔细考虑。本研究评估了广泛使用的膦酸盐、双膦酸盐和环盐磷酸盐原药代谢物对 BxPC3 胰腺癌细胞、GL261-Luc 胶质母细胞瘤细胞和原代培养的小鼠星形胶质细胞的影响。1-萘酚和 2-萘酚的毒性最大。值得注意的是,2-萘酚对 BxPC3 细胞的 ED50 为 21 μM,超过了 ED50 为 82 μM 的 1-萘酚。实时 xCELLigence 实验显示,这两种代谢物在 16 μM 的低浓度下就具有显著的活性。在原代培养的小鼠星形胶质细胞中,所有原药在 128 到 256 μM 的浓度下暴露 4 小时后,细胞活力都会降低。细胞类型对磷酸(烯)原药代谢物的敏感性具有明显的依赖性,正常细胞比相应的肿瘤细胞更易受影响。结果表明,在药物设计和评估过程中必须考虑磷(烯)蚁原药的潜在细胞毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信